Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Personalized Vaccine for Patients With Recurrent Malignant Glioma: a Single-arm, Single-center, Open-labeled Study
A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.
100 Clinical Results associated with Beijing NeoAntigen Biotechnology Co., Ltd.
0 Patents (Medical) associated with Beijing NeoAntigen Biotechnology Co., Ltd.
100 Deals associated with Beijing NeoAntigen Biotechnology Co., Ltd.
100 Translational Medicine associated with Beijing NeoAntigen Biotechnology Co., Ltd.